Aresus Pharma GmbH | Updates

By Sven Schimansky-Wabra

Aresus Pharma above plan


Dear investors,

First of all, we would like to thank you for your previous investments and the trust you have placed in us.

For both of us, Dr. Harrison and myself, working at Aresus with Veregen is really a lot of fun, as we see ourselves confirmed on a daily basis that the product has considerable optimisation and growth potential, which has not yet been fully exploited.

We would like to use today's update to inform you about the activities that have taken place so far. Over the past 2.5 months, our work has focused in particular on two topics: Sales & Process Optimization:



  • Coordination with the contractual partners in China and Mexico has started.
  • The participation at the CPhI in Shanghai (international trade fair of the pharmaceutical industry) made it possible to find a potential partner for North Africa and Turkey (CDA has been signed and conditions are being negotiated).
  • We were also able to contact a Russia expert who can help us import goods into Russia. The approval for Russia has existed since 2017, but has not yet been used.

Process optimizations:

  • The renegotiation of the manufacturing contracts is proceeding as planned. By standardizing the ordering processes, lot sizes can be increased from 60-240kg to 600kg order quantity, thus reducing costs.
  • We were able to implement our own merchandise management system with a direct connection to DATEV in order to prevent manual steps.

In summary, our previous activities are within or even slightly above plan, as we have created additional sales channels with Russia and North Africa, which are not yet included in the current business plan.

In terms of revenue and earnings before taxes, we also currently expect to at least match the annual result for 2019 presented in the business plan and expect to slightly exceed it.

From 2020, we will then start activities to expand the indication as planned. Last week, we already met with the active ingredient supplier in Japan to discuss this issue. The highlight of this meeting was that we were able to agree that we could also use the active ingredient in studies for other indications outside dermatology (in the current agreement between Mitsui-Norin and Medigene, the use of the active ingredient was limited to dermatology). Since there are already several small studies at universities on the use of the active substance as a tablet, we see great potential here in further indications. From our point of view, but also from an external valuation point of view, this represents a major step.

In addition, Dr. Harrison had the opportunity to speak with opinion leaders and specialists in the field of dermatology. In general, all have offered to cooperate, and in particular recommended to start as soon as possible with the expansion of medical indications. A clinical development plan is needed that is in preparation.-

We hope we were able to give you a vivid impression of the current developments. If you have any questions, we will be happy to answer them here in the comment area or by e-mail.

Since the final spurt has started on Companisto, only a few days remain until the investment opportunity is closed. Once the investment target of EUR 700,000 has been reached, we grant an oversubscription buffer of EUR 200,000. Once the EUR 900,000 is reached, however, the investment opportunity is finally closed.


We are looking forward to every further investor!


Best regards,

Sven Schimansky-Wabra


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 765,655




Please note
The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 6 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Aresus Pharma GmbH.
Already registered?    Log in